🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "huge turning point" in the effort against drug-resistant strains of the pathogen, according to health experts.

A Worldwide Health Concern

Gonorrhoea infections are escalating globally, with figures suggesting in excess of 82 million infections annually. Notably increased rates are seen in Africa and countries within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. In England, cases have reached a historical peak, while figures across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an important and timely step in the face of rising global incidence, escalating drug resistance and the very limited available drugs at this time.”

Health officials are particularly alarmed about the increase in drug-resistant strains. The World Health Organization has classified it as a "high-priority threat". A tracking program showed that resistance to standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Gain Approval

One new antibiotic, alternatively called Nuzolvence, was cleared by the US Food and Drug Administration in mid-December for combating gonorrhoea. This infection can lead to major issues, including infertility. Experts hope that focused deployment of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, developed by the drugmaker GSK, gained clearance in concurrent days. This drug, which is additionally indicated for UTIs, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin emerged from a innovative non-profit model for antibiotic development. The non-profit organisation GARDP worked alongside the drug firm Innoviva to see it through.

“This authorization signifies a huge turning point in the treatment of highly resistant gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Research Study Data and Worldwide Availability

Based on data detailed in a major medical journal, the new drug successfully treated more than 90% of uncomplicated infections. This places it at an comparable level with the typical regimen, which combines an injection and a pill. The trial included hundreds of volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, GARDP has the authority to license and sell the drug in a wide range of developing nations.

Clinicians on the front lines have shared optimism. Access to a single-dose, oral treatment such as this is seen as a "revolutionary step" for gonorrhoea control. This is considered crucial to alleviate the strain of the disease for people and to halt the transmission of highly drug-resistant gonorrhoea globally.